43 results about "Alpha-2-Macroglobulin" patented technology

The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other bood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated isidentified, evaluated or classified according to the method of the invention.

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (A2M) from whole blood and or recombinant A2M are provided. Also provided are methods of treating wounds with A2M. Methods for utilizing A2M in combination with other treatments (e.g., platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and / or to prolong the half-life of the protein for treating wounds.

A method of diagnosing tuberculosis (TB) is provided. The method comprises the steps of: detecting a panel of at least four biomarkers selected from the group consisting of complement C3, complement factor H, alpha-2-macroglobulin, loaded Lipoprotein (APO)‑A1, Apolipoprotein APO‑CIII, Apolipoprotein APO‑E, Prealbumin Interferon (IFN)‑γ, Interferon (IFN)‑α2, Interferon Inducible Protein (IP) ‑10, Tumor necrosis factor (TNF)‑α, epidermal growth factor (EGF), macrophage inflammatory protein (MIP)‑1β, soluble CD40 ligand (sCD40L), transforming growth factor (TGF)‑α, vascular endothelial growth factor (VEGF), interleukin 1 receptor antagonist (IL‑1ra), matrix metalloproteinase (MMP)‑2, matrix metalloproteinase (MMP)‑9, binding globulin, c‑reactive protein (CRP), serum amyloid Protein A (SAA), procalcitonin (PCT), ferritin, tissue plasminogen activator (TPA), fibrinogen, and serum amyloid A (SAA). A panel may include more than four of the above-listed biomarkers, such as five, six, seven, or even more of the above-listed biomarkers. Apparatus for carrying out the method are also provided.